TCTR20220708003Unknown3 期
Safety, humoral and cellular immunogenicity after coronavirus disease-19 (COVID-19) vaccination (BNT162b2) in 5 to 12 year-old children after liver transplantation
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5 Years 至 12 Years（—）
- 性别
- All
入选标准
- •Children aged 5-12 years who underwent liver transplant for more than 6 months, clinical stable condition, no history of COVID-19 infection, no history of drug or vaccine allergy.
排除标准
- •Unstable condition, fever, abnormal liver function test, no willing to participate in the study.
研究者
相似试验
招募中
3 期
Safety, humoral and cellular immunogenicity after coronavirus disease-19 (COVID-19) vaccination (BNT162b2) in 12 to 18 year-old children after liver transplantatioImmunization to prevent COVID-19 infectionCOVID-19, vaccination, BNT162b2, adolescent, liver transplant, immunogenicity, safetyTCTR20210830002Chulalongkorn university44
招募中
4 期
Immunologic response to hepatitis B immunization in children post liver transplantatioSafety and efficacy of hepatitis B vaccine, standard compare to double dose in short and long term follow-up.infection, bleeding, painTCTR20180723002Chulalonkorn University72
尚未招募
4 期
Immunity against Influenza virus disease and safety of FluQuadri (marketed vaccine with protection against 4 types of influenza virus) in children of age between 6 and 12 monthsCTRI/2021/10/037161Seth GS Medical College and KEM Hospital
进行中（未招募）
1 期
Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra) administered by the intramuscular route in children 3-11 years oldImmune response to infuenza vaccine in young childrenEUCTR2021-003804-42-NOHelse Bergen HF50
已完成
4 期
Immunity against Influenza virus disease and safety of FluQuadri (marketed vaccine with protection against 4 types of influenza virus) in participants 60 years of age and olderCTRI/2020/09/027913Seth GSMC and KEM Hospital100